Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Provectus gains patent allowance for PH-10 in the EU
Knoxville, Tenn. - Provectus Pharmaceuticals has received allowance of its patent application in the European Union to cover PH-10, as well as other related agents and their use, Businesswire reports.
Knoxville, Tenn.
- Provectus Pharmceuticals has received allowance of its patent application in the European Union for PH-10, as well as other related agents and their use, according to Businesswire.
The pending patents cover topical applications for treatment of psoriasis and eczema. Currently, PH-10 is undergoing a phase 2 clinical trial in New York City for the treatment of moderate to severe psoriasis, Businesswire reports.
Related Videos
Related Content
